Previous 10 | Next 10 |
Phio Pharmaceuticals Announces Upcoming Presentation of PH-894 Data at the AACR Annual Meeting 2022 PR Newswire MARLBOROUGH, Mass. , March 8, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing th...
Phio Pharmaceuticals Initiates In Vivo Studies of INTASYL Based Antivirals Against SARS-CoV-2 Advancement of additional studies is based on positive results from in vitro studies and the ongoing COVID-19 pandemic PR Newswire MARLBOROUGH, Mass. , Feb. 22, 2022 ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips We’re seeing major movement from some hot penny stocks today and are diving into what has them on the rise! Source: John Brueske/Shutterstock.com Before we get too far in. Just remember that penny stocks are ...
Phio Pharmaceuticals Announces Regulatory Clearance of Clinical Trial for PH-762 to Treat Melanoma <span class="legendSpanClass">French regulatory authorities grant Clinical Trial Authorization with dosing of first patient anticipated in the first quarter of 2022</span&...
Phio Pharmaceuticals Scheduled to Participate in the H.C. Wainwright Virtual BioConnect 2022 Conference PR Newswire MARLBOROUGH, Mass. , Jan. 3, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next gener...
Phio Pharmaceuticals Presents Positive New Data On Systemic Immune Response After Local PH-762 Therapy at the SITC 36th Annual Meeting PR Newswire MARLBOROUGH, Mass. , Nov. 12, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a biotechnology c...
Phio Pharmaceuticals (NASDAQ:PHIO): Q3 GAAP EPS of -$0.28 misses by $0.03. Cash Balance of $26.5M Press Release For further details see: Phio Pharmaceuticals EPS misses by $0.03
Phio Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update Lead program, PH-762, is on track to enter first-in-human clinical study in Q1 2022 Presented data at the ESMO Congress 2021 showing Dual-Targeting INTASYL PH-3861 induced a durabl...
Phio Pharmaceuticals Announces Upcoming Presentation at the SITC 36th Annual Meeting PR Newswire MARLBOROUGH, Mass. , Oct. 18, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-on...
Phio Pharmaceuticals Presents New BRD4 Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics PR Newswire MARLBOROUGH, Mass. , Oct. 7, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology compan...
News, Short Squeeze, Breakout and More Instantly...
Phio Pharmaceuticals Corp. Company Name:
PHIO Stock Symbol:
NASDAQ Market:
Phio Pharmaceuticals Corp. Website:
Marlborough, Massachusetts--(Newsfile Corp. - July 12, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) (the "Company"), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells...
Five sites across the U.S. are now participating in the Phase 1b study Marlborough, Massachusetts--(Newsfile Corp. - July 8, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to ...
Marlborough, Massachusetts--(Newsfile Corp. - July 5, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced i...